Featuring Shun Zhou, Ph.D, the R&D Director at Cyagen Biosciences, this webinar promises to be an in-depth learning experience for anyone interested in antibody drug discovery, humanization, and the single B cell screening process.
This topic explores the revolutionary potential of the genome-edited mouse HUGO-Ab, where endogenous VH and VL genes are replaced by fully human VH and VL genes in situ, enabling the generation of fully human antibody molecules. When combined with microfluidic technology-enhanced single B cell screening, this approach allows for the high-throughput and efficient discovery of antibody drug molecules.
Watch the recording here.
About the Speaker
Shun Zhou has a Ph.D. in Molecular Biology and Genetics from the Shanghai Institute for Biological Sciences, Chinese Academy of Sciences, and is a Postdoctoral Fellow in the Department of Biomedical Engineering at Tufts University, USA. With over 10 years of research and development experience in molecular biology, cell biology, and genetics, his work has been published in more than 10 articles in journals such as PNAS and Acta Biomaterialia. Currently serving as the R&D Director at Cyagen Bioscience, he has extensive project research experience in gene editing technologies, Gene and Cell therapy drug research technologies, and antibody discovery technologies, participating in several preclinical projects for antibody drugs and gene and cell therapy drugs.
